ADE LLC’s Biogen BIIB Stock Holding History

ADE LLC’s Portfolio BIIB Stock Details BIIB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-620	Closed	-$175K	–	97
2021 Q3	$175K	Hold	620	–	–	0.16%	77
2021 Q2	$215K	Hold	620	–	–	0.2%	67
2021 Q1	$173K	Hold	620	–	–	0.17%	72
2020 Q4	$152K	Buy	+620	New	+$160K	0.12%	100

Other funds holding BIIB

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

ADE LLC's BIIB Position: Q4 2021 in Review

ADE LLC sold out of Biogen (BIIB) in Q4 2021, closing a stake of 620 shares — an estimated $175K sold.

ADE LLC first reported a position in BIIB in Q4 2020 and held it in 4 quarters. The position peaked at $215K in Q2 2021. 1,009 funds tracked by Wall St. Rank hold BIIB as of Q4 2021.

ADE LLC reported no remaining Biogen position as of Q4 2021 after selling out during the quarter.
ADE LLC sold 620 Biogen shares in Q4 2021, an estimated $175K.
ADE LLC first reported a position in Biogen in Q4 2020 and held it in 4 quarters.
ADE LLC's Biogen position peaked at $215K in Q2 2021.
1,009 funds tracked by Wall St. Rank held Biogen as of Q4 2021.

Based on ADE LLC's 13F filing for Q4 2021, filed 14 Feb 2022.